Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 27, 2015 9:19 AM ET


Company Overview of PsiOxus Therapeutics, Ltd.

Company Overview

PsiOxus Therapeutics, Ltd., a biotechnology company, develops novel therapeutics that address cancer and other clinically unmet diseases. The company provides MT-102, a dual action anabolic catabolic transforming agent for the treatment of cancer cachexia and sarcopenia; and ColoAd1, a chimeric oncolytic virus for the systemic treatment of metastatic cancer. It also offers PolySTAR, a research phase vaccine platform that combines recombinant viral vectors with polymers to shield them from the immune system; and PolyMAP, a research phase adjuvant and immunotherapeutic platform that combines polymers with synthetic adjuvants for immunogenicity. PsiOxus Therapeutics, Ltd. was formerly known as ...

154B Milton Park

Abingdon,  OX14 4SD

United Kingdom

Founded in 2006


44 1235 835 328


44 1869 238 001

Key Executives for PsiOxus Therapeutics, Ltd.

Chief Executive Officer and Director
Founder and Member of Scientific Advisory Board
Finance Director, Company Secretary and Director
Chief Operating Officer
Chief Business Officer
Compensation as of Fiscal Year 2015.

PsiOxus Therapeutics, Ltd. Key Developments

PsiOxus Therapeutics, Ltd. Presents at BIO-Europe 2015, Nov-02-2015

PsiOxus Therapeutics, Ltd. Presents at BIO-Europe 2015, Nov-02-2015 . Venue: Munich, Germany.

PsiOxus Therapeutics, Ltd. Presents at BioEquity Europe 2015, May-19-2015 04:20 PM

PsiOxus Therapeutics, Ltd. Presents at BioEquity Europe 2015, May-19-2015 04:20 PM. Venue: InterContinental Vienna, Vienna, Austria.

PsiOxus Therapeutics Expands Clinical Studies for Immuno-Oncolytic Treatment Following Positive Response to Intravenous Delivery

PsiOxus Therapeutics Ltd. (PsiOxus) has expanded two of its on-going phase I studies using its anti-cancer treatment candidate, enadenotucirev (EnAd), an oncolytic Ad11/Ad3 chimeric group B adenovirus. The expanded studies, introduce a number of additional cancer types into the programme, as a result of phase I data demonstrating the successful tumour delivery of EnAd through intravenous administration. The treatment was generally well tolerated with repeated dosing. PsiOxus has already enrolled its first patients in each indication of the expanded studies. The initial study, a phase I mechanism of action (MoA) study of intra-tumoural and intravenous administration of EnAd in colon cancer patients, has been expanded to include intravenous delivery to three additional tumour types, non-small cell lung, urothelial bladder and renal cell cancer. Initial results of the MoA study in colon cancer found that intravenous delivery was as effective as intra-tumoural delivery. Additionally, virus replication was reported in the tumour tissue but not the surrounding normal cells, while CD8+ T-cells were shown to have successfully infiltrated the tumour, which is not normally seen in most colon cancers. The EVOLVE (EValuating OncoLytic Vaccine Efficacy) trial has expanded to include repeat intravenous dosing of EnAd in metastatic urothelial bladder cancer. EVOLVE is a first in human phase I/II study to determine the dose, safety, tolerability and potential efficacy of EnAd when delivered intravenously to patients with epithelial cancers. It is the first clinical study to report that live replicating oncolytic virus has been recovered directly from the blood stream of cancer patients. Results of this dose escalation study identified a phase II dose for single and repeat dosing of EnAd via intravenous administration. This feature of EnAd distinguishes it from most other oncolytic viruses, where effective delivery to tumours via intravenous administration is not seen.

Similar Private Companies By Industry

Company Name Region
BBI Healthcare Limited Europe
Almac Sciences Limited Europe
Fine Organics Limited Europe
Norgine Limited Europe
Aesica Pharmaceuticals Limited Europe

Recent Private Companies Transactions

Private Placement
May 19, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact PsiOxus Therapeutics, Ltd., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at